3 Australian Founder Led Stocks With Up To 17% Revenue Growth

When the UK government has to pay its highest borrowing cost since 1998 to issue long dated gilts, investors start paying closer attention to who is steering each listed business. Higher funding costs can punish companies with short term thinking. Founder led Australian stocks often come with leaders whose reputations and wealth ride on long term outcomes. This article highlights three such opportunities from the founder focused screener.

The stocks covered below are only a small sample of the founder led opportunities available, with the full screen surfacing 83 more companies with equally compelling stories that are not covered here. If you want to identify which founder operators best fit your style and risk profile, go straight to the Founder-Led Companies screener to filter, analyze, and focus on your highest conviction ideas.

Macquarie Technology Group (ASX:MAQ)

Overview: Macquarie Technology Group runs founder-led cloud, data centre, telecom and cybersecurity services for Australian corporate and government clients.

Operations: Macquarie Technology Group generated about A$235.6 million from Cloud Services & Government, A$105.2 million from Telecom and A$87 million from Data Centres, almost entirely in Australia.

Market Cap: A$1.4b

Founder influence runs through Macquarie Technology Group’s Hello hosted voice platform and hyperscale data centres, giving long-term focused leadership real skin in the game. The stock trades on a premium P/E, carries higher risk borrowings and saw earnings fall in 2026. Potential returns largely depend on how efficiently that capital-heavy infrastructure turns growth into cash and margins.

So the key question is whether Macquarie Technology Group’s capital spend is working hard enough. This is exactly what the DCF valuation analysis for Macquarie Technology Group reveals, including how sensitive returns are to execution risk.

Pro Medicus (ASX:PME)

Overview: Pro Medicus provides founder-led medical imaging software that helps hospitals and radiologists manage, view, and interpret complex scans across major global healthcare markets.

Operations: Pro Medicus generated about A$261.7 million from integrated healthcare software, with most revenue earned in Australia and North America.

Market Cap: A$17.6b

Pro Medicus fits this founder-led screener because Dr. Sam Hupert and his long-tenured leadership team still run the show, aligning daily decisions with a decades-long reputation at stake rather than a short bonus cycle.

"Radiologists at top US hospitals have started demanding it as a condition of employment. They simply won't join institutions that don't run Visage, the company's flagship imaging platform."

What happens to Pro Medicus’ earnings power if that kind of embedded demand meets even a small shift in hospital buying patterns?

If that shift is what you are watching, read the full narrative for Pro Medicus to see how Pro Medicus could accelerate or stall as hospital buying changes.

Mesoblast (ASX:MSB)

Overview: Mesoblast develops founder-led mesenchymal lineage cell therapies, including remestemcel-L and related MPC products, targeting severe inflammatory and cardiovascular diseases.

Operations: Mesoblast reports about US$120 million from development and commercialization of its allogeneic cellular medicines platform.

Market Cap: A$2.9b

Mesoblast fits the Founder-Led Companies screener because leadership remains tied to a single, long-horizon cell therapy platform. In this context, clinical outcomes, not quarterly earnings, define success.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

The real swing factor is how one future clinical and reimbursement inflection ultimately feeds through to pricing power, unit demand and long-term margins.

That clinical and pricing pivot point is exactly what the full narrative for Mesoblast unpacks, including where Mesoblast could accelerate or stall as adoption trends shift.

Curious About Fresh Alternatives To These Picks?

Fresh ideas often move first and prices move next. Spot potential breakout stories and quiet momentum before the crowd catches on. Scan what is still under the radar for now and act now.

• Track resilient cash generators that aim to hold up when others wobble by running the list of solid balance sheet and fundamentals (11 results). Keep your watchlist focused on sturdier opportunities.
• Hunt for payout machines with staying power by checking the 4 dividend fortresses before yields start dropping and the strongest income ideas get fully priced.
• Look at the early phase of an infrastructure buildout by scanning the 39 power grid technology and infrastructure stocks while capital is still shifting into the grid upgrade story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com